公开(公告)号：EP4409043A1

公开(公告)日：2024-08-07

申请号：EP22799869.7

申请日：2022-09-29

申请人： Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) ,  European Molecular Biology Laboratory

发明人： MALATS RIERA, Nuria ,  BORK, Peer ,  KARTAL, Ece ,  MOLINA MONTES, Esther ,  RODRÍGUEZ, Sandra ,  ESTUDILLO, Lidia ,  REAL, Francisco Xavier ,  SCHMIDT, Thomas S.B. ,  ZELLER, Georg ,  WIRBEL, Jakob ,  MAISTRENKO, Oleksandr M.

IPC分类号： C12Q1/6886 ,  C12Q1/689

CPC分类号： C12Q1/6886 ,  C12Q1/689 ,  C12Q2600/1620130101

公开(公告)号：EP4159874A1

公开(公告)日：2023-04-05

申请号：EP21382876.7

申请日：2021-09-29

申请人： Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) ,  European Molecular Biology Laboratory

发明人： MALATS RIERA, Nuria ,  BORK, Peer ,  KARTAL, Ece ,  MOLINA MONTES, Esther ,  RODRÍGUEZ, Sandra ,  ESTUDILLO, Lidia ,  REAL, Francisco Xavier ,  SCHMIDT, Thomas S.B. ,  ZELLER, Georg ,  WIRBEL, Jakob ,  MAISTRENKO, Oleksandr M.

IPC分类号： C12Q1/6886 ,  C12Q1/689

摘要： The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising determining the abundance of several Microbiome species in a faecal sample from said subject, and identifying the subject as having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a pancreatic cancer reference group, or not having pancreatic cancer when the profile of abundance for the analysed species corresponds to a profile of abundance of the analysed species of a reference group not having pancreatic cancer, as well as to a kit and its use for the diagnosis of pancreatic cancer.

公开(公告)号：EP3524237A1

公开(公告)日：2019-08-14

申请号：EP18156520.1

申请日：2018-02-13

申请人： European Molecular Biology Laboratory

发明人： PRUTEANU, Mihaela ,  MAIER, Lisa ,  KUHN, Michael ,  BORK, Peer ,  TYPAS, Athanasios ,  PATIL, Kiran Raosaheb ,  ZELLER, Georg

IPC分类号： A61K31/137 ,  A61K31/4422 ,  A61P31/04

摘要： The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterial activity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.